The impact of KRAS mutational status on patient-reported outcomes in advanced non-small-cell lung cancer: a cross sectional study in France and Germany
Health-related quality of life (HRQoL) studies in patients with advanced non-small-cell lung cancer (NSCLC) according to KRAS mutational status are limited. This study aimed to report real-world evidence on HRQoL outcomes based on KRAS mutational status in patients with advanced NSCLC tumors receivi...
Gespeichert in:
| Hauptverfasser: | , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
2025
|
| In: |
Journal of medical economics
Year: 2025, Jahrgang: 28, Heft: 1, Pages: 13-24 |
| ISSN: | 1941-837X |
| DOI: | 10.1080/13696998.2024.2437324 |
| Online-Zugang: | Verlag, kostenfrei, Volltext: https://doi.org/10.1080/13696998.2024.2437324
|
| Verfasserangaben: | Christos Chouaid, Andromachi Giannopoulou,Alexandra Starry, Björn Stollenwerk, and Farastuk Bozorgmehr |
MARC
| LEADER | 00000naa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 192725387X | ||
| 003 | DE-627 | ||
| 005 | 20250602125302.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 250602s2025 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/13696998.2024.2437324 |2 doi | |
| 035 | |a (DE-627)192725387X | ||
| 035 | |a (DE-599)KXP192725387X | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Chouaid, Christos |e VerfasserIn |0 (DE-588)1185223762 |0 (DE-627)1664579397 |4 aut | |
| 245 | 1 | 4 | |a The impact of KRAS mutational status on patient-reported outcomes in advanced non-small-cell lung cancer |b a cross sectional study in France and Germany |c Christos Chouaid, Andromachi Giannopoulou,Alexandra Starry, Björn Stollenwerk, and Farastuk Bozorgmehr |
| 264 | 1 | |c 2025 | |
| 300 | |b Illustrationen | ||
| 300 | |a 12 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Online veröffentlicht: 09. Dezember 2024 | ||
| 500 | |a Gesehen am 02.06.2025 | ||
| 520 | |a Health-related quality of life (HRQoL) studies in patients with advanced non-small-cell lung cancer (NSCLC) according to KRAS mutational status are limited. This study aimed to report real-world evidence on HRQoL outcomes based on KRAS mutational status in patients with advanced NSCLC tumors receiving second-line or later (2L+) treatment in France and Germany. In this real-world, non-interventional, cross-sectional, multicenter, patient-reported outcome (PRO) study conducted in France (15 contributing sites) and Germany (8 contributing sites), physicians enrolled adult patients with locally advanced and unresectable or metastatic NSCLC with known KRAS mutation status (KRAS G12C, KRAS non-G12C, or KRAS wildtype [WT]), who received a 2L + treatment. Study outcomes included sociodemographic characteristics; HRQoL evaluations based on EORTC Global Health Status QoL scores (QLQ-C30) and EQ-5D-5L scores. Data were analyzed descriptively. Of 156 enrolled patients, data from 149 patients were included in the final analysis (France, n = 103; Germany, n = 46). Median (quartile [Q]1, Q3) age was 67.0 (61.0, 71.0) years; 56.4% of patients were male. In total, 38.9% (n = 58), 26.2% (n = 39), and 34.9% (n = 52) of patients had tumors with KRAS G12C mutation, KRAS non-G12C mutation and WT KRAS, respectively. Mean (±SD) QLQ-C30 Global Health Status QoL scores were 56.99 (20.30) for the overall population, and 56.03 (22.55), 58.97 (18.67) and 56.57 (19.05) for KRAS G12C, non-G12C, and WT subpopulations. In the overall population, moderate-to-extreme problems were reported in all EQ-5D-5L dimensions (range: overall population, 15.5%-39.6%; KRAS G12C, 15.6%-46.6%; non-G12C, 7.8%-23.1%; WT, 21.1%-44.2%). HRQoL was broadly similar across KRAS G12C, non-G12C, and WT subpopulations. | ||
| 650 | 4 | |a Health-related quality of life | |
| 650 | 4 | |a I | |
| 650 | 4 | |a I00 | |
| 650 | 4 | |a I1 | |
| 650 | 4 | |a I19 | |
| 650 | 4 | |a KRAS | |
| 650 | 4 | |a non-small-cell lung cancer | |
| 650 | 4 | |a patient-reported outcome | |
| 650 | 4 | |a real-world data | |
| 650 | 4 | |a symptom burden | |
| 700 | 1 | |a Giannopoulou, Andromachi |e VerfasserIn |4 aut | |
| 700 | 1 | |a Starry, Alexandra |e VerfasserIn |4 aut | |
| 700 | 1 | |a Stollenwerk, Björn |e VerfasserIn |4 aut | |
| 700 | 1 | |a Bozorgmehr, Farastuk |d 1979- |e VerfasserIn |0 (DE-588)141921811 |0 (DE-627)632526734 |0 (DE-576)326848150 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of medical economics |d Abingdon : Taylor & Francis Group, 1998 |g 28(2025), 1, Seite 13-24 |w (DE-627)392234564 |w (DE-600)2156786-4 |w (DE-576)35062416X |x 1941-837X |7 nnas |a The impact of KRAS mutational status on patient-reported outcomes in advanced non-small-cell lung cancer a cross sectional study in France and Germany |
| 773 | 1 | 8 | |g volume:28 |g year:2025 |g number:1 |g pages:13-24 |g extent:12 |a The impact of KRAS mutational status on patient-reported outcomes in advanced non-small-cell lung cancer a cross sectional study in France and Germany |
| 856 | 4 | 0 | |u https://doi.org/10.1080/13696998.2024.2437324 |x Verlag |x Resolving-System |z kostenfrei |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20250602 | ||
| 993 | |a Article | ||
| 994 | |a 2025 | ||
| 998 | |g 141921811 |a Bozorgmehr, Farastuk |m 141921811:Bozorgmehr, Farastuk |d 910000 |d 950000 |d 950900 |d 50000 |e 910000PB141921811 |e 950000PB141921811 |e 950900PB141921811 |e 50000PB141921811 |k 0/910000/ |k 1/910000/950000/ |k 2/910000/950000/950900/ |k 0/50000/ |p 5 |y j | ||
| 999 | |a KXP-PPN192725387X |e 4729859502 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"type":{"bibl":"article-journal","media":"Online-Ressource"},"recId":"192725387X","origin":[{"dateIssuedKey":"2025","dateIssuedDisp":"2025"}],"id":{"eki":["192725387X"],"doi":["10.1080/13696998.2024.2437324"]},"physDesc":[{"extent":"12 S.","noteIll":"Illustrationen"}],"relHost":[{"part":{"issue":"1","pages":"13-24","extent":"12","volume":"28","year":"2025","text":"28(2025), 1, Seite 13-24"},"language":["eng"],"title":[{"title_sort":"Journal of medical economics","title":"Journal of medical economics","subtitle":"JME"}],"pubHistory":["1.1998 -"],"recId":"392234564","origin":[{"dateIssuedKey":"1998","publisher":"Taylor & Francis Group ; PJB Publ. ; Informa Healthcare","dateIssuedDisp":"1998-","publisherPlace":"Abingdon ; Richmond ; New York, NY"}],"titleAlt":[{"title":"JME"}],"type":{"media":"Online-Ressource","bibl":"periodical"},"note":["Gesehen am 03.06.2022"],"disp":"The impact of KRAS mutational status on patient-reported outcomes in advanced non-small-cell lung cancer a cross sectional study in France and GermanyJournal of medical economics","id":{"zdb":["2156786-4"],"issn":["1941-837X"],"eki":["392234564"]}}],"note":["Online veröffentlicht: 09. Dezember 2024","Gesehen am 02.06.2025"],"name":{"displayForm":["Christos Chouaid, Andromachi Giannopoulou,Alexandra Starry, Björn Stollenwerk, and Farastuk Bozorgmehr"]},"person":[{"display":"Chouaid, Christos","role":"aut","given":"Christos","family":"Chouaid"},{"family":"Giannopoulou","display":"Giannopoulou, Andromachi","role":"aut","given":"Andromachi"},{"display":"Starry, Alexandra","given":"Alexandra","role":"aut","family":"Starry"},{"display":"Stollenwerk, Björn","given":"Björn","role":"aut","family":"Stollenwerk"},{"display":"Bozorgmehr, Farastuk","role":"aut","given":"Farastuk","family":"Bozorgmehr"}],"title":[{"title_sort":"impact of KRAS mutational status on patient-reported outcomes in advanced non-small-cell lung cancer","title":"The impact of KRAS mutational status on patient-reported outcomes in advanced non-small-cell lung cancer","subtitle":"a cross sectional study in France and Germany"}],"language":["eng"]} | ||
| SRT | |a CHOUAIDCHRIMPACTOFKR2025 | ||